The article focuses on evaluating the safety and effectiveness of a lower dose intradermal injection strategy for the Modified Vaccinia Ankara-Bavarian Nordic vaccine (Jynneos) compared to the standard subcutaneous dose, amidst efforts to manage vaccine supply during a global smallpox outbreak.